Lipigon Pharmaceuticals AB (LPGO) — Strategic Asset Allocation Index
Lipigon Pharmaceuticals AB (LPGO) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of Skr61.00K plus long-term investments of Skr-) total Skr61.00K, measured against net assets of Skr27.59 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Lipigon Pharmaceuticals AB Strategic Asset Allocation Index (2021–2022)
This chart shows how Lipigon Pharmaceuticals AB's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of Skr61.00K against net assets of Skr27.59 Million SEK. Explore Lipigon Pharmaceuticals AB cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of Lipigon Pharmaceuticals AB.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.9% | Skr72.00K | Skr72.00K | Skr- | Skr3.87 Million | ▲ +1.4 pp |
| 2021 | 0.4% | Skr96.00K | Skr96.00K | Skr- | Skr22.96 Million | — |